A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties

• Main Authors: Jie Zhao (Author), Liangfeng Jiang (Author), Haodong Yang (Author), Lan Deng (Author), Xiaoqing Meng (Author), Jian Ding (Author), Sixing Yang (Author), Le Zhao (Author), Wei Xu (Author), Xiaolong Wang (Author), Zhenping Zhu (Author), Haomin Huang (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Targeting PD1/PDL1 with blocking antibodies for cancer therapy has shown promising benefits in the clinic, but only approximately 20-30% of patients develop durable clinical responses to the treatment. Bispecific antibodies (BsAbs) that combine PD1/PDL1 blockade with the modulation of another immune...